{
  "doc_id": "IPT_50-2022-Tecentriq",
  "created_date": "2022",
  "country": "ES",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "REPORT REPORT PT/V1/50/Report Report (Tecentriq®) Publication Publication date: Carcinoma Carcinoma (CHC) cancer cancer (1). age age (65-70 65-70 years), women women (2). virus virus (VHB). C C (VHC) with with some/initial initial (cirrhosis cirrhosis [Child-Pugh A], asymptomatic (performance status (PS) 0), tumors tumors < or or dissemination) initial initial (patients patients (PS 0) function function [and and B] nodules nodules ≤ 3 cm), intent intent (percutaneous percutaneous ablation), by by 60%-80%. intermediate intermediate (extrahepacious extrahepacious disease). recent recent years; therapies therapies (transarterial chemoembolization).sorafenib sorafenib (Nexavar®) survival survival (SG) with __ MEDTERM$ratio ratio (HR) 69 69 [confidential interval (CI) of 95% 0. 0.0006] (11).line line (table table 1). document document (15). __MEDTERMM15_ (TECENTRIQ®) renal renal and/__MedTERM16__ __MedTERM16__ (19) 5-15 5-15 mg/150 150 (phase III) (15, 20). randomised randomised 2:1 (study study + IMBRAVE 150 (stage III)-15). criteria criteria were: performed performed by: geographical region (Asia [excluding Japan] the the world), macrovascular invasion and/spread spread (presence vs absence), baseline alphafetoprotein (AFP) levels (< 400 ng/mL vs ≥400 ng /mL) status status (0 vs 1).15 15 mg/rate rate (complete complete response) disease disease (mRECIST), response response (success success progression) the the patient'life life (and and EORTIC-QLQ–HCC18 test). atezolizumabMEDTREM___ atezolizumabMEDTREM___ (336 patients) M2_ M2_ (165 patients), men men (82%) status. status. 82% and and 15% B. B. 40% and and 49% of of 26% and and 15% patients patients (28.6%) patients patients (39.4%) 28. 28.6%, _REDTERM0_ _REDTERM0_ – respectively respectively (HR 0.58; 95% 42-0. 42-0.79; p<for for SG). objective, objective, 93% EORTQLQQC30 EORTQLQQC30 (minimum one question) and and 80% one one question), the the patient'respectively respectively (63, 63, 95% CI, 0.46-0-0.8.85) full full scale; respectively respectively (53, 53, 95% 39-0. 39-0.73) physical physical condition; respectively respectively (62, 62, 95% 08. 08.84) 1 1 (155). 6 6 (15, 20). IMbrave150 IMbrave150 (August 2019) _MEDTERM0__MEDTERMM___ _MEDTERM0__MEDTERMM___ – _TERm__- __TERM (98.2%) _MEDERTRMM0___-_MEDSTERM1__PROMTERM__ _MEDERTRMM0___-_MEDSTERM1__PROMTERM__ -_MEDDERM_ [98.1%) overall overall were: arterial hypertension (29.8%), fatigue (20%), fatigue (20.4%), proteinuria (20.1%), bilirubin bilirubin (13.1%)), aspartate aspartate amino-transferase transferase (12.2%), nausea (122%, nauseuseause (12.9%, cough (12.9%), cough (11.9%,9%, 90%, infusion infusion (11.2%, __MEDM3__MFF__YM __MEDM3__MFF__YM (+M)_MEMBERM1=2. 2.0% (10/4993) months months (range: 3 3 months). group group of_MEDERTM0–months. months. + from from 69% to 28% from from 19% to 29 %, hepatitis hepatitis (defined diagnosis and/or laboratory disorders) of of 10% from from 66% to 76% analysis analysis (21). 15. 15.5% to to ESMO'curves curves (22). results results (9 9 months), evaluation evaluation (21). result result (9 9 months), result result (algorithm algorithm (23). patients patients (24). __Medterm2_ __Medterm2_ (25). hypertension hypertension (14% vs 23%) syndrome syndrome (11% vs 3%). __labelled __labelled 2:1 (__TERM) 84. 84.8% (95% 9-88. 9-88.7) 67. 67.2% (95%3-73. 3-73.1) of of ______MEDTERMS0_–__ENTERM1_; and 72.2% (99% SG.179.4) 54. 54.6% month month (95 % 2-64. 2-64.0) for for +% MEDTERMM2_–rate rate (_MEDTERM293_; 29.8% 1. 1.1) of of 8% versus <1% with MEDTER M2__MTERM+__WTERM-__ –_MEDERTM1–between between 8% and < 1% group group __MEDSTERM0______-group group =MEDTERMS0-_ALL-WELTERM(1) and 37.2% 5 5 - 33% (CITTERM2). of of _$27. 27.3% was was (95% (C 95, 99% – _MEDERTM0-__MEDDERM1_ _MEDERTM0-__MEDDERM1_ (98.7% vs 98.2% respectively).combination combination _MEDSTERM0___-of of _MEDterM0–__redtermm1___ (125 patients, 38%) __MEDARTEM2___ __MEDARTEM2___ (30. 30.8%). 84. 84.8% (95% 9-88. 9-88.7%) 67. 67.2% (95%3-73. 3-73.1%) and and 52% of of atezolizumab_EMTERM1__; and 72.2% (95%) 65.1-79.4% 54. 54.6% month month (95% 2-64. 2-64.0%), and 40% median median [%7-8. 7-8.3] __ __ MEDTERM01__=median median (% 0-5. 0-5.6] 59 59 [% 95% p p <0.0001]. advanced advanced and/carcinoma carcinoma and/ Advanced Advanced and/Pharmacy Pharmacy (DGGCCSSSNSYSYF) of of TECENTRICTRIQ® (_MEDDERTERME0___) at at least- Med. Med. 2020;382(20):Food Food & Hepatol. Hepatol. 2016;14:124–I, I, Taylor- Available Available from: Hepatocellular Hepatocellular carcinoma: J J databases/fda-approves-_MEDTER M0__-plus- Gastroenterol order 2008; 14: 17. 17.___-unresect-hepattocellulular-hepatoellcellular-IMbrave IMbrave 150) name name Tecentriq®-Avastin® 1200mg-atezolizum 1200mg-atezolizum 15mg/artery artery (Fatigue Fatigue frequency) Medical Medical (HDM). Efficacy Efficacy (pivotal pivotal studies) IMBRAVE IMBRAVE 150) ib ib (_MEDSTERM167_ _MEDSTERM167_ Lenvima® Oral 8 mg/24h (weight <60 nigh)",
      "start_page": 1,
      "end_page": 11
    },
    {
      "heading": "global (A) and survival",
      "text": "EJMoa1915745/suppl_file/progression progression (B) (pdf pdf (Mayo Access)",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "(B)",
      "text": "Imbrave150 Imbrave150 (A) Survival Survival (SG) (time ___MEDTERMM2_R (95% CI) p (N=165) to to (N =336) any any cause) n n (%) 96 (28.6) 65 (39.4) 0.58 (0.42-0.79)a P<months months (CI 95%) 2 2 (10.4-NA) to to (NC=336) Deaths, n % (28.6%) 65 (39) 65 (59(4)) 0.58 (39 4) 0 0 (0 = 165) P < 34-07-07-9 months (2 95% CI 95%) months, months, % (9 95% CI 95) 12-months, 12-months, % 95% (9 95%) (9 95%CI) overall overall (B) variables variables (N=336) (N =rate rate (complete complete response) ratio, ratio, % (9 95% CI) value value P<rates, rates, % (95 95% CI 95%) 2 2 (28-1-38,6) 13.3 (value value <response response (or or success) of of >the the patient'life life (EORTC EORTC QLQQ-C30) 2 2 (6,0-0-CIC) 3,6 (months months ( 95% CI 95) Rate Rate (9 95%) 0.63 (0,46-0,85) 1 1 (5-5, 5-5, (6,9-9,9-5-9-9-9, 9-9-9-59-90-97-9 9 - 5-9-95-95, (9-9- 59-95 - IC), 9 % - 6 – 5-5 - 5 - 5-5 – 7 % - 5 months, 95% - 5 % - 3 – 6 % - ISC ISC - 5 – 9 % – 5 - 9 9 – 6 – C C - 9 - 6 - 6 % – 6 - 5– – 5 – 8 % - weight weight - 5 years, 9",
      "start_page": 12,
      "end_page": 16
    },
    {
      "heading": "heating heating <none>",
      "text": "Row 1: Row Row 2: antiligating antiligating the",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "heating heating <none>",
      "text": "Row 1: S. S., Ryoo, B.-Y., Hsu, C.-Row Row 2: Row Row 3: hepatocellular carcinoma (GO30140): Row Row 4: Row Row 5: 21(6), 808–820.",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heating heating <none>",
      "text": "Row 1: Row Row 2: Name_MEDTERM0______MEDTERm1____MEDterM3__ Row 3: Trade nameTecentriq®-AvastinLenvimaNexavar® Row 4: PresentationIntravenousOralRow 5: Posology1200mg-_MEDERTRM4__15mg/weeks8 weeks8 mg/24h (weight <60kg) 12mg/24h(weight ≥60 kg)400mg/12h Row 6: or or nonYesYes=Yes Row 7: Adverse effects (of of frequency)Row Row 8: Day Day (HDM).",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "heating heating <none> (column 1)",
      "text": "Row 1: Row Row 2: Name_MEDTERM0__-bev Row 3: _MedTERM___-bEV Row 4: Trade nameTecentriq®-Avastin Row 5: PresentationIntravenosa Row 6: Posology1200mg-atezolizum 15mg/Row Row 7: Row Row 8: Adverse effects (of of frequency)Row Row 9: Médico Médico (HDM). Row Row 10: Effectiveness (pivotal pivotal studies)IMbrave IMbrave 150)",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "heating heating <none> (column 2)",
      "text": "Row 1: Row Row 2: Row 3: Row Row 4: Row 5: Row 6: vacizumab Row 7: ® Row 8: Row 9: Row Row 10: Row 11: al Row 12: Row Row 13: ib (test Row 14: Pági",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "heating heating <none> (column 3)",
      "text": "Row 1: Row Row 2: Row 3: Row Row 4: row 5: _MEDterM1__ Row 6: =_MEDTREM___ Row 7: Lenvima Row 8: Oral Row 9: 8 mg/24h (weight <60 12mg/24h) (weight≥60 Row 10: Yes Row 11: Row Row 12: Row Row 13: sorafen sorafen (test REFLECT) Row 14: de de 16",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "heating heating <none> (column 4)",
      "text": "Row 1: Row 2: Com Row 3: Row 4: Row 5: ALTE Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: 0kg) 0kg). Row 12: Row 13: l Row 14: io Row 15: nib Row 16:",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "heating heating <none> (column 5)",
      "text": "Row 1: Row 2: Row Row 3: __MEDTERM0_ (Row Row 4: row 5: ERNATIVAS Row 6: core 7: Soraf Row 8: soraf Row 9: Nexa Row 10: oral Row 11: 400m Row 12: Yes Row 13: Row Row 14: Régim row 15: )Row Row 16: +",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "heating heating <none> (column 6)",
      "text": "Row 1: Row 2: SIMILAR",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "heating heating <none> (column 6)",
      "text": "Row 1: fenib Row 2: Row Row 3: var® Row 4: Row 5: mg/12h Row 6: Row 7: Row Row 8: Row Row 9: placebo placebo (Asia-Pacific Asia-Pacific trial)",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "heating heating <none> (column 2)",
      "text": "Row 1: Row Row 2: Row 3: of of 16",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "heating heating <none> (column 3)",
      "text": "Row 1: Comisi ve150 (15). Row 2: Row 3:",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "heating heating <global ageing (A) and survival> (column 2)",
      "text": "Row 1: global victory (A) and supervivenable in: EJMoa1915745/suppl_file/ne Row 2: Row 3: Row 4: of of 16",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading <(B)> (column 2)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heating heating <(B)> (column 4)",
      "text": "Row 1: Row 2: Row 3: of of 16",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading <(B)> (column 7)",
      "text": "Row 1: Row 2: Comisi Row 3: Row 4: Row 5:",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "hearing hearing <(B)> (from previous page)",
      "text": "Row 1: Row Row 2: MEDTERM1_ MEDTERM1_ (N=336)_REDTERM2_ (n=165))pNNT (C 95%) Row 3: row 4: Global survival (SG) (timeHR (95) Row 5: Row Row 6: any any cause)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "hearing hearing <(B)> (from previous page)",
      "text": "Row 1: Atezolizumab- Row 2: Row Row 3: (N=336)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "hearing hearing <(B)> (from previous page)",
      "text": "Row 1: Sorafenib Row 2: (N=165)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "hearing hearing <(B)> (from previous page)",
      "text": "Row 1: NNT (IC Row 2: 95%)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "hearing hearing <(B)> (from previous page)",
      "text": "Row 1: Sorafenib Row 2: (N=165)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "hearing hearing <(B)> (from previous page)",
      "text": "Row 1: Atezolizumab- Row 2: Row Row 3: (N=336)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "hearing hearing <(B)> (from previous page)",
      "text": "Row 1: Sorafenib Row 2: (N=165)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "hearing hearing <(B)> (from previous page)",
      "text": "Row 1: NNT (IC Row 2: 95%)",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "hearing hearing <(B)> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: Secondal variables(N=336)( N=165) Row 4: rate rate (complete complete response) Row 5: ratio, ratio, % (95% CI) 3 3 (22.5-32.5)11,9 (7.4-18,0) row 6: P valueP<Row Row 7: rates, rates, % (95% CI) 2 2 (28,1-386,6)13,3 (8,4-19.6) Row 8: P valuesP< Row Row 9: Responsibility duration (or or éxitus) Branch 10: duration duration >6 months, %,6-059, 6-059,1",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heating heating <(B)> (column column 1)",
      "text": "Row 1: Row Row 2: __MEDERTME___REDTERM1_ __MEDERTME___REDTERM1_ (N=336)-MEDTERm2_P Row 2: primary primary variables:__ __ (n=336)-_MEDERTERM2__(N=165)-p Row 3: 4 Row 4: +5; overall survival (SG) (timeHR (95%) Row 5: Row Row 6: any any cause) row 7: n n (%) 96 (28,6) 65 (39.4) 0,05, (0,-Row Row 10: -4-0-0 years (95% C 95%) NANA13,2 (10,4-NA) Row Row 12:: _____ MEDTERM - average, average, % months, % month, % (95 (9 95%)84),84,84,8% (99% 95) €844,848484,4%,4 4 %,4 %, 4 (95-14, 4",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heating heating <(B)> (column column 1)",
      "text": "Row 1: Row Row 2: Row Row 3: Secondary variables(N=336)( N=165 Row 4: rate rate (complete complete response) Row 5: ratio, ratio, % (95% CI) 3 3 (22,5-32.5)11,9 (Row Row 6: P valueP<Row Row 7: rates, rates, % (95% CI) 2 2 (28,1-38,6)13,3 (Row Row 8: PP value<Row Row 9: Performance duration (or or éxitus) Roam 10: duration duration >6 months, %87,6,1",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heating heating <(B)> (column column 2)",
      "text": "Row 1: Row 2: NNT (95% CI) Row 3: 7 (5-15) row 4: row 5: NNT (IC95) roan 6: 8(5-24) core 7: 8 (5-28) Row 8: NNT (95% IC) ruh 9: 15 (4-10)row 10:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heating heating <(B)> (column column 2)",
      "text": "Row 1: Row 2: nib Row 3: (5) Row 4: row 5: 18,0) Row 6: row 7: 19,6) Row 8: core 9: tail 10: branch 11: east 12: 7,0)• Row 13: roan 14: 6,2) row 15: axis 16: 6, 2) row 17: +",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "hearing hearing <(B)> (from previous page)",
      "text": "Row 1: Row 2: row 3: row 4:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heating heating <(B)> (column column 1)",
      "text": "Row 1: Row 2: row 3:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heating heating <(B)> (column column 2)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heating heating <(B)> (column column 2)",
      "text": "Row 1: global victory (A) Row Row 2: Row 3:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heating heating <(B)> (column column 3)",
      "text": "Row 1: Perviv Row 2: Row 3:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heating heating <(B)> (column column 4)",
      "text": "Row 1: Row Row 2: Row 3: of of 16",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heating heating <(B)> (column column 5)",
      "text": "Row 1: sion (B) Row Row 2: Row 3:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heating heating <(B)> (column column 6)",
      "text": "Row 1: Row 2: Row 3: Row Row 4: Row 5:",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heating heating <(B)> (column column 2)",
      "text": "Row 1: GO30140 GO30140 (20). Row 2: Row 3: IMbrave150 IMbrave150 (15). Row 4: Row 5: of of 16",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "heating heating <(B)> (column column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "heating heating <(B)> (column column 6)",
      "text": "Row 1: Row 2: Comisi Row 3: Row 4: Row 5: Row 6: Row 7:",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "heating heating <(B)> (column column 2)",
      "text": "Row 1: Row Row 2: Row 3: Row 4: unity Row 5:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "heating heating <(B)> (column column 3)",
      "text": "Row 1: Row Row 2: Row 3:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "heating heating <(B)> (column column 4)",
      "text": "Row 1: hepatocellular oma (22) Row 2: Row 3: of of 16",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "heating heating <(B)> (column column 5)",
      "text": "Row 1:). Row 2: Row 3:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "heating heating <(B)> (column column 6)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "heating heating <(B)> (column column 8)",
      "text": "Row 1: Row 2: Comisi Row 3: Row 4: Row 5:",
      "start_page": 16,
      "end_page": 16
    }
  ]
}